fulvestrant has been researched along with Neoplasms in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Almaraz Postigo, S; Montero, JC | 1 |
| Braiteh, FS; Hamilton, E; Huang, M; Liaw, DCH; Pant, S; Strauss, JF; Ulahannan, SV | 1 |
| Bates, AM; Burkel, BM; Emma, SE; Jin, WJ; Morris, ZS; Nystuen, EJ; O'Leary, KA; Ponik, SM; Schuler, LA; Sriramaneni, RN; Sumiec, EG | 1 |
| Chu, T; Li, B; Li, S; Lu, Z; Nie, G; Qi, F; Song, Z; Sukumar, S; Wang, M; Wei, J; Wu, S; Xu, J; Zhang, C; Zhu, F | 1 |
| Poulter-Clark, H; Spencer, J; Yip, F; Zavery, B | 1 |
| Barghout, SH | 1 |
| Donders, EN; Ganesh, AN; Lak, P; Shoichet, BK; Shoichet, MS; Torosyan, H | 1 |
| Bergamaschi, A; Katzenellenbogen, BS; Mir, M; Popescu, G | 1 |
| Casa, AJ; Cui, X; Dearth, RK; Lee, AV; Litzenburger, BC | 1 |
| Keely, NO; Meegan, MJ | 1 |
| Robb, EL; Stuart, JA | 1 |
| Mariani, SM | 1 |
| Burka, LT; Chu, AC; Garner, CE; Ho, JW; Ho, PW; Ho, SL; Kung, MH; Kwok, KH; Leung, KC; Ramsden, DB | 1 |
| Annable, T; Collins, KI; Frost, P; Greenberger, LM; Komm, BS; Lyttle, CR; Miller, CP; Satyaswaroop, PG; Zhang, Y | 1 |
3 review(s) available for fulvestrant and Neoplasms
| Article | Year |
|---|---|
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Fulvestrant; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Thalidomide; Ubiquitination | 2021 |
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Male; Neoplasms; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Signal Transduction; Treatment Outcome | 2008 |
Targeting tumors using estrogen receptor ligand conjugates.
Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Drug Design; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Ligands; Neoplasm Staging; Neoplasms; Receptors, Estrogen | 2009 |
1 trial(s) available for fulvestrant and Neoplasms
| Article | Year |
|---|---|
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Enzyme Inhibitors; Fulvestrant; Humans; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase | 2023 |
11 other study(ies) available for fulvestrant and Neoplasms
| Article | Year |
|---|---|
Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Fulvestrant; Neoplasms; Neuregulins; Phosphatidylinositol 3-Kinases; Signal Transduction | 2023 |
Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy.
Topics: Animals; Estrogen Antagonists; Estrogens; Fulvestrant; Immunosuppressive Agents; Immunotherapy; Mice; Neoplasms; Receptors, Estrogen | 2023 |
Nanoparticle-Based Combination Therapy Enhances Fulvestrant Efficacy and Overcomes Tumor Resistance in ER-Positive Breast Cancer.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Fulvestrant; Mice; Neoplasms; Receptors, Estrogen; Swine | 2023 |
Putting patients first: an inventive service delivering cancer treatment at home.
Topics: Administration, Cutaneous; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Delivery of Health Care; Denosumab; Fulvestrant; Goserelin; Home Care Services; Humans; Middle Aged; Neoplasms; Patient Safety; Patient Satisfaction; Surveys and Questionnaires; Trastuzumab; Treatment Outcome; Young Adult | 2019 |
Triggered Release Enhances the Cytotoxicity of Stable Colloidal Drug Aggregates.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Survival; Colloids; Delayed-Action Preparations; Drug Liberation; Endosomes; Fulvestrant; Humans; Neoplasms; Transferrin | 2019 |
Highly sensitive quantitative imaging for monitoring single cancer cell growth kinetics and drug response.
Topics: Cell Proliferation; Cluster Analysis; Colorimetry; Drug Screening Assays, Antitumor; Estradiol; Fulvestrant; Humans; Kinetics; MCF-7 Cells; Microscopy, Interference; Neoplasms; Precision Medicine; Receptors, Estrogen; Single-Cell Analysis | 2014 |
Targeting Mutant AKT in Cancer.
Topics: Clinical Trials, Phase I as Topic; Drug Synergism; Estradiol; Fulvestrant; Humans; Mutation; Neoplasms; Neoplastic Cells, Circulating; Precision Medicine; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Resveratrol interacts with estrogen receptor-β to inhibit cell replicative growth and enhance stress resistance by upregulating mitochondrial superoxide dismutase.
Topics: Animals; Antioxidants; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression; Humans; Hydrogen Peroxide; Mice; Mitochondria; Neoplasms; Nitriles; Phenols; Propionates; Pyrazoles; Resveratrol; Stilbenes; Stress, Physiological; Superoxide Dismutase; Up-Regulation | 2011 |
Conference report--cancer research 2004--top of the class March 27-March 31, 2004; Orlando, Florida.
Topics: Androgen Antagonists; Animals; Breast Neoplasms; Cell Differentiation; Cell Proliferation; DNA Repair; Estradiol; Female; Fulvestrant; Genetic Therapy; Humans; Male; Neoplasms; Prostatic Neoplasms; Replication Protein A; Stem Cells | 2004 |
Estrogenic phenol and catechol metabolites of PCBs modulate catechol-O-methyltransferase expression via the estrogen receptor: potential contribution to cancer risk.
Topics: Actins; Blotting, Western; Catechol O-Methyltransferase; Catechols; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Environmental Pollutants; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Fulvestrant; Humans; Neoplasms; Phenols; Polychlorinated Biphenyls; Receptors, Estrogen; Risk | 2008 |
A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Topics: Animals; Binding, Competitive; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Organ Size; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Sensitivity and Specificity; Tamoxifen; Time Factors; Tumor Cells, Cultured; Uterus; Xenograft Model Antitumor Assays | 2001 |